My Cart [ 0 ]
Home > Antibodies > Research-Grade Biosimilars > Galiximab Biosimilar, CD80 Monoclonal Antibody

Galiximab Biosimilar, CD80 Monoclonal Antibody

Cluster of differentiation 80, CD80, B7-1, B7, B7.1, BB1, CD28LG, CD28LG1, LAB7

Catalog No. Product Name Size List Price (US$) Quantity
C048P Galiximab Biosimilar, CD80 Monoclonal Antibody 1 mg 250.00
C048P Galiximab Biosimilar, CD80 Monoclonal Antibody 5 mg 750.00
C048P Galiximab Biosimilar, CD80 Monoclonal Antibody 20 mg 2000.00
Description

C048P: Galiximab Biosimilar, CD80 Monoclonal Antibody

Recombinant Humanized IgG1 Monoclonal Antibody.
Isotype: Human IgG1 kappa.
Source: The anti-human CD80 monoclonal antibody galiximab biosimilar was produced in mammalian cells.
Specificity/Sensitivity: The in vivo grade galiximab biosimilar specifically binds to the human CD80.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by galiximab.
Form of Antibody: 0.2 uM filtered solution, pH 6.0, no stabilizers or preservatives.
Endotoxin: <1 EU/mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.

Shipping: The research grade galiximab biosimilar is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.

Background

A humanized IgG1 monoclonal antibody directed against CD80, the natural ligand for the T-cell antigen CD28 which mediates T-cell and B-cell adhesion. Galiximab binds to CD80 expressed on the cell surfaces of follicular lymphomas, resulting in antibody-dependent cell-mediated cytotoxicity (ADCC). CD80 is expressed on activated B-cells and gamma-interferon-stimulated monocytes and is often expressed at low levels on the surfaces of follicular lymphoma cells and other lymphoid malignancies.

Galiximab, an IgG(1) anti-CD80 antibody, binds to CD80, a costimulatory molecule involved in T-cell activation. Reduction in lesional, activated T cells induces improvement in psoriatic plaques.

Related Links

See our Privacy Policy